HK1071304A1 - Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b - Google Patents

Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b

Info

Publication number
HK1071304A1
HK1071304A1 HK05104181.6A HK05104181A HK1071304A1 HK 1071304 A1 HK1071304 A1 HK 1071304A1 HK 05104181 A HK05104181 A HK 05104181A HK 1071304 A1 HK1071304 A1 HK 1071304A1
Authority
HK
Hong Kong
Prior art keywords
formation
preventing
complement pathway
pathway inhibitors
inhibitors
Prior art date
Application number
HK05104181.6A
Other languages
English (en)
Inventor
Michael S C M Fung
Cecily C Sun
Meisheng M Lu
William W Sun
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23214536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1071304(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1071304A1 publication Critical patent/HK1071304A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
HK05104181.6A 2001-08-17 2005-05-19 Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b HK1071304A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31313701P 2001-08-17 2001-08-17
PCT/US2002/026074 WO2003015819A1 (fr) 2001-08-17 2002-08-17 Inhibiteur de la voie du complement se fixant a c5 et a c5a sans empecher la formation de c5b

Publications (1)

Publication Number Publication Date
HK1071304A1 true HK1071304A1 (en) 2005-07-15

Family

ID=23214536

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05104181.6A HK1071304A1 (en) 2001-08-17 2005-05-19 Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b

Country Status (14)

Country Link
US (6) US7432356B2 (fr)
EP (1) EP1425042B2 (fr)
JP (2) JP4958387B2 (fr)
CN (2) CN100391537C (fr)
AT (1) ATE360441T1 (fr)
AU (1) AU2002331601B2 (fr)
BR (1) BRPI0211953B8 (fr)
CA (1) CA2457461C (fr)
DE (1) DE60219801T3 (fr)
ES (1) ES2283594T5 (fr)
HK (1) HK1071304A1 (fr)
MX (2) MX342385B (fr)
PT (1) PT1425042E (fr)
WO (1) WO2003015819A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4958387B2 (ja) 2001-08-17 2012-06-20 ジェネンテック， インコーポレイテッド Ｃ５ｂの形成を妨害することなくｃ５及びｃ５ａに結合する補体経路阻害剤
EP1569958B1 (fr) 2002-12-02 2009-02-18 Resistentia Pharmaceuticals AB Techniques et produits pour le traitement d'inflammation utilisant un polypeptide comprenat un segment d'acides amines c5 autogeniques et un segment d'acides amines non autogeniques
AU2004241069B2 (en) 2003-05-15 2010-09-09 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
DK1755674T3 (en) 2004-05-14 2015-02-09 Alexion Pharma Inc PROLONGED SURVIVAL OF A allograft by inhibiting complement activity
US20080076138A1 (en) 2005-03-02 2008-03-27 Astellas Pharma Inc. Novel Pd Marker for Histone Deacetylase Inhibitor
CN101193654A (zh) * 2005-06-14 2008-06-04 赛托斯生物技术公司 抗原偶联物及其用途
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
KR20180002911A (ko) * 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
PL1988882T3 (pl) 2006-03-02 2015-04-30 Alexion Pharma Inc Wydłużanie przeżycia alloprzeszczepu poprzez inhibowanie aktywności dopełniacza
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
ZA200900954B (en) * 2006-08-22 2010-05-26 G2 Inflammation Pty Ltd Ant-C5aR antibodies with improved properties
PL2061810T3 (pl) 2006-09-05 2015-05-29 Alexion Pharma Inc Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał
KR20160092061A (ko) * 2006-11-02 2016-08-03 제넨테크, 인크. 인간화 항-ｄ 인자 항체
EP3689912A1 (fr) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
EP4238993A3 (fr) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène capable de se lier à deux ou plusieurs molécules d'antigène de manière répétée
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2010075257A1 (fr) 2008-12-22 2010-07-01 Chemocentryx, Inc. Antagonistes de c5ar
EP2327725A1 (fr) 2009-11-26 2011-06-01 InflaRx GmbH Groupes caractéristiques à liaison anti-C5a avec une activité à blocage élevé
SG185383A1 (en) 2010-04-30 2012-12-28 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
PL2585064T3 (pl) 2010-06-24 2017-09-29 Chemocentryx, Inc. Antagoniści C5AR
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP2468295A1 (fr) 2010-12-21 2012-06-27 Affiris AG Vaccins à base de peptides de la proteine C5a du complement
DK3798230T3 (en) 2011-06-06 2022-10-31 Novo Nordisk As Terapeutiske antistoffer
WO2013126006A1 (fr) * 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides se fixant au composant c5 du complément humain
US9133269B2 (en) 2012-08-24 2015-09-15 Anaptysbio, Inc. Humanized antibodies directed against complement protein C5
CN105392803B (zh) * 2013-05-08 2019-12-06 诺和诺德股份有限公司 C5aR拮抗剂的用途
US20140335546A1 (en) * 2013-05-10 2014-11-13 G J Carroll Pty Ltd Devices and Methods for Determining the Risk of Developing a Serious Infection
CN107318267B (zh) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
TR201911279T4 (tr) 2013-08-28 2019-08-21 Affibody Ab Mutasyona uğramış bir yapı iskelesine sahip polipeptidlerin bağlanması.
WO2015028558A1 (fr) 2013-08-28 2015-03-05 Swedish Orphan Biovitrum Ab (Publ) Polypeptides stables se liant au c5 du complément humain
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US10227397B2 (en) * 2014-03-20 2019-03-12 Inflarx Gmbh Inhibitors of C5a for the treatment of viral pneumonia
BR112016025312A2 (pt) 2014-05-01 2017-10-17 Genentech Inc variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
CN113121415A (zh) 2014-09-29 2021-07-16 凯莫森特里克斯股份有限公司 制备C5aR拮抗剂的方法和中间体
SG11201607165YA (en) 2014-12-19 2016-09-29 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
CN107428823B (zh) 2015-01-22 2021-10-26 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
EP3390442B1 (fr) 2015-12-18 2023-11-08 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-c5 et leurs procédés d'utilisation
BR112018014222A2 (pt) 2016-01-14 2018-12-11 Chemocentryx, Inc. método de tratamento da glomerulopatia c3
UA124734C2 (uk) 2016-06-14 2021-11-10 Рідженерон Фармасьютікалз, Інк. Антитіло проти с5 і його застосування
AU2017285763B2 (en) 2016-06-17 2024-02-01 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies and methods of use
EP3494991A4 (fr) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Composition pour la prophylaxie ou le traitement de maladies liées à il-8
PL3577135T3 (pl) 2017-01-31 2023-12-04 Chugai Seiyaku Kabushiki Kaisha Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
EA201992091A1 (ru) * 2017-03-06 2020-02-04 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Анти-c5 антитела и их применение
CA3057146A1 (fr) * 2017-03-23 2018-09-27 The Trustees Of The University Of Pennsylvania Anticorps anti-c5a et utilisations de ceux-ci
EP3717916A1 (fr) 2017-11-29 2020-10-07 H. Hoffnabb-La Roche Ag Dosage d'anticorps anti-médicament à interférence de cible supprimée
JP2021506241A (ja) 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃ５抗体組み合わせ物およびその使用
EP3829628B1 (fr) 2018-08-01 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Composition pharmaceutique destinée à être utilisée dans le traitement ou la prévention d'une maladie liée à c5
CN114466660A (zh) 2019-07-31 2022-05-10 豪夫迈·罗氏有限公司 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
CA3144923A1 (fr) 2019-07-31 2021-02-04 Alexandre Antoine Bernard SOSTELLY Regime posologique et d'administration pour le traitement ou la prevention de maladies liees a c5 par l'utilisation de l'anticorps anti-c5 crovalimab
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
JP2023530977A (ja) 2020-06-16 2023-07-20 エフ． ホフマン－ラ ロシュ アーゲー 試料中の抗体の遊離抗原を決定するための方法
WO2023050233A1 (fr) * 2021-09-29 2023-04-06 The Trustees Of The University Of Pennsylvania Anticorps anti-c5a humanisés et leurs utilisations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
ES2054667T3 (es) * 1986-04-28 1994-08-16 Cetus Oncology Corp Anticuerpos monoclonales contra c5a y des-arg74-c5a, su produccion y uso.
US5260203A (en) † 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5256766A (en) * 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
CA2186108A1 (fr) * 1994-03-23 1995-09-28 Scott A. Rollins Procede permettant de reduire les dysfonctionnements des systemes immunitaire et hemostatique pendant la circulation extra-corporelle
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5562904A (en) 1994-07-21 1996-10-08 Alexion Pharmaceuticals, Inc. Retroviral transduction of cells using soluble complement inhibitors
AU3729295A (en) * 1994-09-23 1996-04-09 Alexion Pharmaceuticals, Inc. Methods for the treatment of inflammatory joint disease
US5572904A (en) * 1995-01-05 1996-11-12 Minculescu; Mihai C. Oscillation lever arm engine
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
JP4958387B2 (ja) 2001-08-17 2012-06-20 ジェネンテック， インコーポレイテッド Ｃ５ｂの形成を妨害することなくｃ５及びｃ５ａに結合する補体経路阻害剤

Also Published As

Publication number Publication date
MXPA04001301A (es) 2004-07-08
BRPI0211953B8 (pt) 2021-05-25
US20150086572A1 (en) 2015-03-26
US8907072B2 (en) 2014-12-09
AU2002331601B2 (en) 2006-04-13
CA2457461C (fr) 2013-12-24
MX342385B (es) 2016-09-27
US20130230522A1 (en) 2013-09-05
US8206716B2 (en) 2012-06-26
US7432356B2 (en) 2008-10-07
PT1425042E (pt) 2007-07-11
CN101387646B (zh) 2016-08-10
EP1425042A4 (fr) 2004-09-29
BRPI0211953B1 (pt) 2019-05-28
ES2283594T5 (es) 2016-03-15
ATE360441T1 (de) 2007-05-15
EP1425042B1 (fr) 2007-04-25
DE60219801T2 (de) 2008-01-17
ES2283594T3 (es) 2007-11-01
CA2457461A1 (fr) 2003-02-27
US20160200805A1 (en) 2016-07-14
JP2005508889A (ja) 2005-04-07
JP4958387B2 (ja) 2012-06-20
CN1553813A (zh) 2004-12-08
US20080118508A1 (en) 2008-05-22
BR0211953A (pt) 2005-02-01
JP5752374B2 (ja) 2015-07-22
US20120301483A1 (en) 2012-11-29
CN100391537C (zh) 2008-06-04
WO2003015819A1 (fr) 2003-02-27
DE60219801D1 (de) 2007-06-06
DE60219801T3 (de) 2016-06-16
US20030129187A1 (en) 2003-07-10
EP1425042A1 (fr) 2004-06-09
JP2011051987A (ja) 2011-03-17
CN101387646A (zh) 2009-03-18
EP1425042B2 (fr) 2016-02-10
US8372404B2 (en) 2013-02-12

Similar Documents

Publication Publication Date Title
HK1071304A1 (en) Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
WO2008140653A3 (fr) Anticorps anti-facteur b humanisé
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
NZ592786A (en) Methods and compositions for treating complement-associated disorders using eculizumab
MXPA05011886A (es) Metodos y composiciones para la prevencion y tratamiento de septicemia.
NO20092718L (no) Antagonist-anti-Notch 3-antistoffer og deres anvendelse i forebyggelsen og behandlingen av Notch 3-relaterte sykdommer
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
MX2021000398A (es) Moleculas de anticuerpo que se unen a pd-l1 y cd137.
GEP20135826B (en) Novel antibodies used to treat cancer
AU2017236063A1 (en) Monoclonal antibodies against the active site of factor XI and uses thereof
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2021012769A (es) Anticuerpos bloqueadores cd73.
AU2024202263A1 (en) Antibodies to PMEL17 and conjugates thereof
EP1878441A3 (fr) Inhibiteurs de chemin d'accès complémentaires liant C5 et C5a sans empêcher la formation de C5b
SG148190A1 (en) Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer
WO2002094194A3 (fr) Compositions et methodes d'inhibition d'une metastase
MX2022001411A (es) Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5.
DE602005025459D1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
WO2019246176A8 (fr) Anticorps anti-facteur xii/xiia et leurs utilisations
UA96917C2 (ru) Антитела, направленные против пептида бета-амилоида, и способы их применения
DE50014789D1 (de) Kombination von verbindungen, welche die biologischen wirkungen von tnf-alpha und cd95l hemmen, in einem arzneimittel
MX2022009525A (es) Inhibidores y usos de los mismos.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200817